COCRYSTAL PHARMA NEW O.N. (F:8CC) — Market Cap & Net Worth
Market Cap & Net Worth: COCRYSTAL PHARMA NEW O.N. (8CC)
COCRYSTAL PHARMA NEW O.N. (F:8CC) has a market capitalization of $11.21 Million (€9.59 Million) as of May 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #26596 globally and #2297 in its home market, demonstrating a -5.79% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying COCRYSTAL PHARMA NEW O.N.'s stock price €1.14 by its total outstanding shares 13784065 (13.78 Million).
COCRYSTAL PHARMA NEW O.N. Market Cap History: 2020 to 2026
COCRYSTAL PHARMA NEW O.N.'s market capitalization history from 2020 to 2026. Data shows change from $220.45 Million to $18.37 Million (-30.44% CAGR).
COCRYSTAL PHARMA NEW O.N. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how COCRYSTAL PHARMA NEW O.N.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 8CC by Market Capitalization
Companies near COCRYSTAL PHARMA NEW O.N. in the global market cap rankings as of May 5, 2026.
Key companies related to COCRYSTAL PHARMA NEW O.N. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $109.06 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #357 globally with a market cap of $73.69 Billion USD.
- UCB SA (BR:UCB): Ranked #519 globally with a market cap of $50.85 Billion USD ( €43.50 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #567 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.06 Billion | $429.85 |
| #357 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.69 Billion | $709.21 |
| #519 | UCB SA | BR:UCB | $50.85 Billion | €228.50 |
| #567 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
COCRYSTAL PHARMA NEW O.N. Historical Marketcap From 2020 to 2026
Between 2020 and today, COCRYSTAL PHARMA NEW O.N.'s market cap moved from $220.45 Million to $ 18.37 Million, with a yearly change of -30.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €18.37 Million | +41.61% |
| 2025 | €12.97 Million | -72.24% |
| 2024 | €46.73 Million | +87.10% |
| 2023 | €24.98 Million | -9.88% |
| 2022 | €27.72 Million | -74.40% |
| 2021 | €108.29 Million | -50.88% |
| 2020 | €220.45 Million | -- |
End of Day Market Cap According to Different Sources
On May 5th, 2026 the market cap of COCRYSTAL PHARMA NEW O.N. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.21 Million USD |
| MoneyControl | $11.21 Million USD |
| MarketWatch | $11.21 Million USD |
| marketcap.company | $11.21 Million USD |
| Reuters | $11.21 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About COCRYSTAL PHARMA NEW O.N.
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C … Read more